Literature DB >> 30806860

Cumulative Inflammation Could Be a Risk Factor for Intestinal Failure in Crohn's Disease.

Yoshifumi Watanabe1, Norikatsu Miyoshi1, Shiki Fujino1, Hidekazu Takahashi1, Naotsugu Haraguchi1, Taishi Hata1, Chu Matsuda1, Hirofumi Yamamoto1, Yuichiro Doki1, Masaki Mori1, Tsunekazu Mizushima2,3.   

Abstract

BACKGROUND: Intestinal failure is the most critical complication of Crohn's disease. Intestinal failure requires home parenteral nutrition, which worsens the quality of life of the patients and sometimes causes life-threatening complications. AIMS: The purpose of this study was to investigate the incidence and risk factors for intestinal failure in Crohn's disease.
METHODS: We performed a retrospective analysis of Crohn's disease patients (162 cases) at Osaka University Hospital between January 2000 and December 2017. Kaplan-Meier analysis was used to investigate the cumulative incidence of intestinal failure. To identify the risk factors of intestinal failure, patient characteristics were analyzed by multivariate analysis, including disease classification, surgical history, medical treatment other than surgery, and cumulative inflammation was calculated using the average C-reactive protein value and disease duration.
RESULTS: The cumulative incidence of intestinal failure 5, 10, and 15 years after Crohn's disease diagnosis was 2.6%, 3.4%, and 8.6%, respectively. Multivariate analysis identified the following as independent risk factors for intestinal failure in Crohn's disease: residual small intestinal length < 200 cm (odds ratio 7.51, 95% confidence interval 2.14-29.96), non-use of anti-tumor necrosis factor-alpha therapy (3.34, 1.22-10.74), and cumulative inflammation (1.01, 1.001-1.038). We created a new predictive nomogram consisting of these risk factors.
CONCLUSIONS: Intestinal failure occasionally occurred during long-term treatment of Crohn's disease. Cumulative inflammation for the first time, in addition to short residual small intestinal length and non-use of anti-tumor necrosis factor-alpha therapy, was shown to be potential risk factors for intestinal failure in Crohn's disease.

Entities:  

Keywords:  Crohn’s disease; Incidence; Malabsorption syndromes; Parenteral nutrition; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 30806860     DOI: 10.1007/s10620-019-05553-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

Review 1.  AGA technical review on short bowel syndrome and intestinal transplantation.

Authors:  Alan L Buchman; James Scolapio; Jon Fryer
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

2.  Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.

Authors:  Ase Riis; Tom C Martinsen; Helge L Waldum; Reidar Fossmark
Journal:  Scand J Gastroenterol       Date:  2012-04-04       Impact factor: 2.423

3.  Risk factors for first operation in Crohn's disease.

Authors:  G Basilisco; M Campanini; B Cesana; T Ranzi; P Bianchi
Journal:  Am J Gastroenterol       Date:  1989-07       Impact factor: 10.864

4.  Determinants of home parenteral nutrition dependence and survival of 268 patients with non-malignant short bowel syndrome.

Authors:  Aurelien Amiot; Bernard Messing; Olivier Corcos; Yves Panis; Francisca Joly
Journal:  Clin Nutr       Date:  2012-08-23       Impact factor: 7.324

Review 5.  Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure.

Authors:  Palle B Jeppesen
Journal:  JPEN J Parenter Enteral Nutr       Date:  2014-01-31       Impact factor: 4.016

6.  Crohn's disease patients with chronic intestinal failure receiving long-term parenteral nutrition: a cross-national adult study.

Authors:  K Elriz; V Palascak-Juif; F Joly; D Seguy; P Beau; C Chambrier; M Boncompain; E Fontaine; D Laharie; G Savoye; E Lerebours
Journal:  Aliment Pharmacol Ther       Date:  2011-08-16       Impact factor: 8.171

7.  Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.

Authors:  Mamoru Watanabe; Toshifumi Hibi; Kathleen G Lomax; Susan K Paulson; Jingdong Chao; M Shamsul Alam; Anne Camez
Journal:  J Crohns Colitis       Date:  2011-08-26       Impact factor: 9.071

Review 8.  Diagnosis and management of inflammatory bowel disease in children.

Authors:  Stephanie B Oliveira; Iona M Monteiro
Journal:  BMJ       Date:  2017-05-31

Review 9.  Recurrence of Crohn's disease after resection.

Authors:  J G Williams; W D Wong; D A Rothenberger; S M Goldberg
Journal:  Br J Surg       Date:  1991-01       Impact factor: 6.939

Review 10.  Gastroenterological surgery in Japan: The past, the present and the future.

Authors:  Hugh Colvin; Tsunekazu Mizushima; Hidetoshi Eguchi; Shuji Takiguchi; Yuichiro Doki; Masaki Mori
Journal:  Ann Gastroenterol Surg       Date:  2017-04-25
View more
  4 in total

1.  Crohn's disease and short bowel syndrome.

Authors:  Philippe Pinton
Journal:  Surg Today       Date:  2022-06-29       Impact factor: 2.549

2.  Development and evaluation of a Japanese prediction model for low anterior resection syndrome after rectal cancer surgery.

Authors:  Masakatsu Paku; Norikatsu Miyoshi; Shiki Fujino; Tsuyoshi Hata; Takayuki Ogino; Hidekazu Takahashi; Mamoru Uemura; Tsunekazu Mizushima; Hirofumi Yamamoto; Yuichiro Doki; Hidetoshi Eguchi
Journal:  BMC Gastroenterol       Date:  2022-05-13       Impact factor: 3.067

Review 3.  Chronic intestinal failure and short bowel syndrome in Crohn's disease.

Authors:  Aysegül Aksan; Karima Farrag; Irina Blumenstein; Oliver Schröder; Axel U Dignass; Jürgen Stein
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

4.  Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn Disease in Olmsted County, Minnesota.

Authors:  Zeinab Bakhshi; Siddhant Yadav; Bradley R Salonen; Sara L Bonnes; Jithinraj Edakkanambeth Varayil; William Scott Harmsen; Ryan T Hurt; William J Tremaine; Edward V Loftus
Journal:  Crohns Colitis 360       Date:  2020-10-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.